ima203
Recurrent Solid Tumors
Immatics US, Inc.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Recurrent Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ono-4538 Ono Pharmaceutical Co., Ltd. | Phase 1 | CCC |
Atezolizumab Genentech, Inc. | Phase 1 | CC |
ro7566802 Genentech, Inc. | Phase 1 | CC |
Bet Bromodomain Inhibitor Zen-3694 Haider Mahdi | Phase 1 | CC |
Niraparib Haider Mahdi | Phase 1 | CC |
it-141 Intezyne Technologies, Inc. | Phase 1 | CC |
Same molecule, other indications
ima203 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →